Billionaires Holding CLDN

BILLIONAIRE ALLOCATION SHARES OWNED (M) % CO AVG. COST RETURN

FUNDAMENTALS

  • N/A
    PE

  • 0.0
    Yield

  • 23.9M
    Shares Outstanding

  • 291.1M
    Market Cap

News & Insights

ABOUT

CLDN

Celladon Corporation, a clinical-stage biotechnology company, focuses on developing cardiovascular gene therapy and calcium dysregulation. The company’s lead product candidate includes MYDICAR that uses genetic enzyme replacement therapy to correct the Sarco/endoplasmic reticulum Ca 2+ -ATPase 2a...

Apple And Berkshire Hathaway: When Two Worlds Collide

NEWS

Icahn: Best Bet On Commodities

READ MORE